• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EDP Renewables Starts Construction on 240-Megawatt Texas Solar Park

    9/20/22 10:00:00 AM ET
    $BMY
    $FB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Internet and Information Services
    Technology
    Get the next $BMY alert in real time by email

    Houston, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- EDP Renewables North America (EDPR NA), a leading renewable energy developer and operator in North America, announces the start of construction on its 240-megawatt (MW) Cattlemen I Solar Park in Milam County, Texas.

    Cattlemen Solar Park, which was developed and constructed and will be operated by EDPR NA, will bring a wealth of economic benefits to Milam County and the greater central Texas region through millions of dollars that will be paid to local landowners, a projected $55 million in taxes that will be paid to support area schools and community services, and millions of dollars that will be spent locally during the project's construction and multi-decade operational life. Cattlemen will also support local jobs – both in the 400 employment opportunities created during construction and the several full-time team members who will be employed to safely run and perform routine maintenance on the park during operations. Once online in 2023, Cattlemen's generation will be equivalent to the consumption of more than 37,000 average Texas homes. Cattlemen will also save more than 304 million gallons of water and avoid more than 271,000 tons of CO2 each year that would be needed by conventional generation sources to produce the same amount of energy capacity as the solar park.

    "Cattlemen is EDP Renewables' first solar park in Texas and will soon be our largest operational solar park in our North American portfolio," Kris Cheney, EDP Renewables North America Executive Vice President – Central and Western Regions and Mexico, Environmental Affairs, and Energy Storage Analytics said. "The Milam County community has been a great partner throughout Cattlemen's development. As we move closer to operation, we look forward to continuing that partnership as a contributing member of the community and expanding upon our relationship with the landowners, local officials, and residents."

    EDP Renewables is a clean energy leader in Texas. The company's North American headquarters is in Houston and it operates six wind energy projects throughout the state, including two phases of the Lone Star Wind Farm, two phases of the Los Mirasoles Wind Farm, the Reloj del Sol Wind Farm, and the Wildcat Creek Wind Farm. The projects' total operating capacity is 1,089 MW, which generate enough electricity to annually power more than 236,000 average homes in Texas. EDPR's Texas presence totals an estimated $1.9 billion in capital investment and more than 550 jobs.

    Cattlemen has two long-term commercial agreements in-place for the project: a 156-MW power purchase agreement (PPA) with Meta (NYSE:FB) and a 60-MW PPA with Bristol Myers Squibb (NYSE:BMY). Cattlemen Solar Park is the second PPA that EDP Renewables and Meta have executed; the companies' first PPA was a 139-MW contract for EDPR NA's 200-MW Headwaters II Wind Farm in Indiana.

    Multimedia resources include:

    • EDPR NA: Fact Sheet
    • Cattlemen Solar Park: Fact Sheet
    • EDPR NA Texas: Fact Sheet
    • Economic benefits of solar: Fact Sheet
    • Solar Power in North America: Video

    ###

    About EDP Renewables North America

    EDP Renewables North America LLC (EDPR NA), its affiliates, and its subsidiaries develop, construct, own, and operate wind farms and solar parks throughout North America. Headquartered in Houston, Texas, with 58 wind farms, nine solar parks, and eight regional offices across North America, EDPR NA has developed more than 8,800 megawatts (MW) and operates more than 8,200 MW of onshore utility-scale renewable energy projects. With more than 950 employees, EDPR NA's highly qualified team has a proven capacity to execute projects across the continent.

    For more information, visit www.edpr.com/north-america.

    About EDP Renewables

    EDPR NA is a wholly owned subsidiary of EDP Renewables (Euronext: EDPR), a global leader in

    the renewable energy sector. EDPR is the fourth largest renewable energy producer worldwide with a presence in 28 markets across Europe, North America, South America and Asia Pacific. Based in Madrid and with main regional offices in Houston, São Paulo and Singapore, EDPR has a robust development portfolio with first-class assets and a market-leading operational capability in renewables. These include wind onshore, utility scale and distributed solar, wind offshore (through its 50/50 JV - OW) and technologies complementary to renewables such as batteries and green hydrogen. EDPR's employee-centered policies resulted in its recognition as a Top Workplace 2022 in the United States, Top Employer 2022 in Europe (Spain, Italy, France, Romania, Portugal and Poland) and Brazil, as well as its inclusion in the Bloomberg Gender-Equality Index.

    EDPR is a division of EDP (Euronext: EDP), a leader in the energy transition with a focus on decarbonization. Besides its strong presence in renewables (with EDPR and hydro operations), EDP has an integrated utility presence in Portugal, Spain and Brazil including electricity networks, client solutions and energy management. EDP – EDPR's main shareholder – has been listed on the Dow Jones Index for 14 consecutive years, recently being named the most sustainable electricity company on the Index.

    Attachments

    • EDP Renewables Logo
    • Cattlemen Solar Park Logo


    Blair Matocha
    EDP Renewables North America
    713-356-2415
    blair.matocha@edp.com
    
    Get the next $BMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $FB

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    Bristol-Myers Squibb Company
    $BMY
    12/15/2025$61.00Neutral → Buy
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    12/12/2025$62.00Neutral → Buy
    Guggenheim
    Bristol-Myers Squibb Company
    $BMY
    11/13/2025$45.00Sector Perform
    Scotiabank
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $BMY
    $FB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Yale Phyllis R

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    7/2/26 4:20:09 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Samuels Theodore R. Ii

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    7/2/26 4:18:30 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rice Derica W

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    7/2/26 4:17:30 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

    Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems to scale proprietary AI models, compress discovery timelines, and advance its vision of collaborative hybrid intelligence, where AI scientists work alongside researchers to pursue first- and best-in-class medicines Bristol Myers Squibb (NYSE:BMY, "BMS")), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences. The e

    7/20/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

    Application based on results from SUCCESSOR-2 trial showing oral CELMoD mezigdomide in combination with carfilzomib and dexamethasone significantly improved progression-free survival vs. standard of care in this patient population The U.S. FDA has assigned a target action date of May 13, 2027 Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM). Mezigdomide is an oral cereblon E3 ligase modulator, or CELMoD, for the treatment of multiple myeloma. The FDA has granted

    7/13/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Quest to Repair What Multiple Sclerosis Takes Away

    AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is determin

    6/24/26 8:30:00 AM ET
    $QNTM
    $NVS
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Bristol-Myers with a new price target

    RBC Capital Mkts initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $60.00

    2/25/26 7:49:08 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers upgraded by UBS with a new price target

    UBS upgraded Bristol-Myers from Neutral to Buy and set a new price target of $65.00

    1/7/26 8:28:35 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    SEC Filings

    View All

    SEC Form 11-K filed by Bristol-Myers Squibb Company

    11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    6/5/26 1:45:57 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Bristol-Myers Squibb Company

    11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    6/5/26 1:45:22 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Bristol-Myers Squibb Company

    11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    6/5/26 1:44:43 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

    SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

    2/9/23 11:12:40 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Meta Platforms Inc. (Amendment)

    SC 13G/A - Meta Platforms, Inc. (0001326801) (Subject)

    2/14/22 4:03:05 PM ET
    $FB
    Internet and Information Services
    Technology

    SEC Form SC 13G/A filed by Meta Platforms Inc. (Amendment)

    SC 13G/A - Meta Platforms, Inc. (0001326801) (Subject)

    2/10/22 8:11:43 AM ET
    $FB
    Internet and Information Services
    Technology

    $BMY
    $FB
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

    Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET. Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call. A replay of the webcast will be available here approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol M

    6/18/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit

    6/17/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Reports First Quarter Financial Results for 2026

    Bristol Myers Squibb (NYSE:BMY) today reported first quarter 2026 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed first quarter 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, April 30, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Th

    4/30/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $FB
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

    WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik

    4/20/26 8:00:00 AM ET
    $ARDX
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

    Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

    5/6/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care